The routine, twice-weekly asymptomatic Covid-19 testing by pharmacy staff can be paused from the end of August.
The health regulator announced that regular asymptomatic testing for Covid-19 will be paused in all remaining health and care settings from 31 August 2022.
Currently all pharmacy staff test twice-weekly for Covid-19, using a self-administered Lateral Flow Device (LFD) test at home.
"Prevalence of Covid-19 in the community has fallen and remains at a comparatively low level as we emerge from the current Omicron wave. This means that the
likelihood that individuals entering healthcare settings are infectious has also reduced and the relative risk of onward transmission into these settings is lower."
Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday announced that fluoroquinolone antibiotics must only be
administered when no other antibiotics are appropriate for use.
It elaborated that fluoroquinolones given systemically (by mouth, injection, or inhalation) should only be prescribed "when other recommended antibiotics have
failed, will not work due to resistance, or are unsafe to use in an individual patient."
Previous regulations on fluoroquinolones stated that this class of antibiotics should not be prescribed for mild to moderate or self-limiting infections, or
non-bacterial conditions.
Further restrictions have been introduced after receiving reports from patients who have experienced long-lasting or disabling reactions following use of
fluoroquinolones, the MHRA revealed.
Dr Alison Cave, MHRA Chief Safety Officer, said: "Patient safety is our top priority. We have listened to the experience of patients regarding long-lasting
and potentially irreversible adverse reactions following use of fluoroquinolone antibiotics, in some cases prescribed for mild-to-moderate infections.